logo-loader
viewC4X Discovery Holdings plc

Full interview: 'Momentum building' within C4X Discovery portfolio as it looks to license NRF-2 programme

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix updates Proactive London's Andrew Scott on progress across the firm's portfolio.

He says they're very confident of delivering deals in the near future.

Dix adds licensing discussions with potential partners for two of its early-stage drugs, while collaborations with two life sciences groups are making progress.

Quick facts: C4X Discovery Holdings plc

Price: 37 GBX

AIM:C4XD
Market: AIM
Market Cap: £21.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings plc named herein, including the promotion by the Company of C4X Discovery Holdings plc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

C4X Discovery in advanced discussions to partner its 'world-leading' NRF-2...

Clive Dix, chief executive of C4X Discovery Holdings plc (LON:C4XD), recaps on recent significant developments following the release of their interims for the six months to the end of January 2019. Dix says confidential discussions with multiple potential partners are being held for its...

on 30/4/19

2 min read